Equities

Regen BioPharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Regen BioPharma Inc

Actions
  • Price (USD)0.0036
  • Today's Change0.000 / 1.43%
  • Shares traded1.36m
  • 1 Year change-95.36%
  • Beta2.7389
Data delayed at least 15 minutes, as of Feb 06 2026 19:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Regen BioPharma Inc. is a biotechnology company. The Company is focused on developing treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. Its primary program consists of identifying small molecules that inhibit or express NR2F6 to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

  • Revenue in USD (TTM)236.58k
  • Net income in USD-1.27m
  • Incorporated2012
  • Employees1.00
  • Location
    Regen BioPharma Inc4700 Spring Street, Suite 304LA MESA 91942United StatesUSA
  • Phone+1 (619) 722-5505
  • Fax+1 (619) 330-2328
  • Websitehttps://regenbiopharmainc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Health Advance Inc-100.00bn-100.00bn272.41k3.00--0.0135----------0.0212----------------------------0.0356--100.00---21.75------
Windtree Therapeutics Inc0.00-48.83m306.75k14.00---------8.38-8.380.00-0.34490.00----0.00-172.27-48.72-791.65-52.57------------22.36------72.96---42.51--
THC Farmaceuticals Inc7.58k-60.45k351.75k2.00--0.1375--46.41-0.0036-0.00360.00050.1411------3,790.00--------100.00---1,591.69------0.2051--348.43--5,170.19------
Regen BioPharma Inc236.58k-1.27m453.14k1.00------1.92-0.0875-0.08750.0088-0.15951.09--1.58---585.02-205.58---------538.72-457.54---0.3821----0.0016.55-90.72------
Longevity Health Holdings Inc1.46m-5.74m516.88k15.00------0.3547-5.22-5.221.26-2.230.50771.1147.3197,153.34-199.84------57.86---393.63--0.2676----------36.91------
Regenerative Medical Technology Grop Inc5.04m-7.06m551.81k1.00------0.1095-0.5629-0.56290.4019-2.401.3024.9569.50---182.18-177.25----59.7664.83-140.06-465.060.0784-0.0279----70.44167.3043.31------
Bio Path Holdings Inc0.00-11.18m554.53k10.00---------1.71-1.710.00-0.8660.00----0.00-611.66-81.00---90.58-----------65.76--------38.46------
Helix BioMedix Inc2.07m-2.58m609.46k8.00--0.3887--0.295-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Hepion Pharmaceuticals Inc0.00-9.17m662.36k22.00--0.4065-----13.39-13.390.000.28610.00-------245.96-65.13-417.51-73.82-----------5.250.0606------73.04------
Data as of Feb 06 2026. Currency figures normalised to Regen BioPharma Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.